Use of 4β-Hydroxycholesterol Plasma Concentrations as an Endogenous Biomarker of CYP3A Activity: Clinical Validation in Individuals With Type 2 Diabetes.
Autor: | Gravel S; Faculty of Pharmacy, Université de Montréal, Montréal, Québec, Canada.; CRCHUM-Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada., Chiasson JL; CRCHUM-Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.; CHUM, Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.; Faculty of Medicine, Université of Montréal, Montréal, Québec, Canada., Gaudette F; CRCHUM-Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada., Turgeon J; Faculty of Pharmacy, Université de Montréal, Montréal, Québec, Canada.; CRCHUM-Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada., Michaud V; Faculty of Pharmacy, Université de Montréal, Montréal, Québec, Canada.; CRCHUM-Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada. |
---|---|
Jazyk: | angličtina |
Zdroj: | Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2019 Oct; Vol. 106 (4), pp. 831-840. Date of Electronic Publication: 2019 Jun 05. |
DOI: | 10.1002/cpt.1472 |
Abstrakt: | The relevance of endogenous 4β-hydroxycholesterol (4β-OHC) plasma concentrations or of the 4β-OHC/total cholesterol concentration ratio (4β-OHC ratio) as surrogate markers of cytochrome P450 3A (CYP3A) activity was evaluated in individuals with (n = 38) or without (n = 35) type 2 diabetes (T2D). Midazolam was used as a comparator to validate exploratory measures of phenotypic CYP3A activity. Metabolic ratios of orally administered midazolam in nondiabetic and diabetic populations correlated significantly with 4β-OHC (r (© 2019 The Authors Clinical Pharmacology & Therapeutics © 2019 American Society for Clinical Pharmacology and Therapeutics.) |
Databáze: | MEDLINE |
Externí odkaz: |